Use of in vitro assays in selection of compatible platelet donors.
Although HLA-matched platelet transfusions are of value in the support of some alloimmunized thrombocytopenic patients, poor posttransfusion increments can be observed following HLA-matched platelet transfusions and conversely good posttransfusion increments may result after HLA-mismatched platelet transfusions. We have explored the possibility that in vitro assays in addition to HLA typing might better select compatible donors for refractory recipients. Our studies suggested that a platelet migration inhibition assay is predictive of platelet transfusion responses in HLA-compatible and incompatible donor-recipient pairs, while lymphocytotoxicity is predictive of posttransfusion increments only in HLA-incompatible donor-recipient pairs. Granulocytotoxicity, microleukoagglutination, and capillary leukoagglutination showed no value in predicting platelet transfusion increments, either in HLA-compatible or incompatible donor-recipient pairs.
D000741:Anemia, Aplastic / Q000628:therapy; D001782:Blood Donors; D001792:Blood Platelets / Q000276:immunology*; D001803:Blood Transfusion; D002464:Cell Migration Inhibition; D003602:Cytotoxicity, Immunologic; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D017713:Platelet Transfusion; D011289:Preleukemia / Q000628:therapy
D006680:HLA Antigens